West Pharmaceutical Services Names New President Of Pharmaceutical Packaging Systems

EXTON, Pa., Oct. 7, 2014 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) has appointed Karen Flynn President of the company's Pharmaceutical Packaging Systems business. Pharmaceutical Packaging Systems is a global business unit within West, and is the company's largest, generating annual sales revenue of nearly $1 billion.

"Karen has a strong track record of growing revenue, while maintaining high team engagement and motivation, and has been incredibly successful in the management of our Americas business," said Donald E. Morel, Jr., Chairman and Chief Executive Officer, West. "As West enters a very exciting period of anticipated growth, the Board and I are confident in Karen's ability to serve as one of our company's key business leaders."

Karen Flynn brings more than 28 years of experience to this role. Most recently, she held the position of President, Americas Region, Pharmaceutical Packaging Systems, where she was responsible for the Americas regional business segment, including both the manufacturing and commercial aspects of the business. From 2000 to 2008, Flynn was a part of Catalent (formerly known as a division of Cardinal Health), where she worked in Sales Management, finishing her career there as Vice President, Global Accounts. Prior to Catalent, Flynn spent 15 years at West, in roles spanning Quality, R&D, Technical Services and Sales. In 2008, she rejoined West as Vice President, Sales, Americas.

Flynn holds a Bachelor of Science in Pre-Professional Studies (Pre-Med) from The University of Notre Dame, a Master of Science in Business Administration from Boston University, and a Master of Science in Engineering from The University of Pennsylvania. She is a member of the Healthcare Businesswomen's Association, the Forum of Executive Women, and serves on the Downingtown STEM Academy Advisory Board.

About West
West works side-by-side with its healthcare partners from concept to the patient, designing and manufacturing packaging, diagnostic and delivery systems that promote the efficiency, reliability and safety of their products. Every day, West is leading the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched and growing knowledge base of relevant pharmaceutical product testing, development and packaging. Based in Exton, Pa., West supports its customers from sales, manufacturing, customer support and research and development locations in North and South America, Europe, Asia and Australia. Established in 1923, West had 2013 sales totaling $1.4 billion.

West and the diamond logo and By your side for a healthier world are registered trademarks or trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as "may," "should," "could," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," or "potential" or the negative of these words and phrases or similar words or phrases, which are predictions of or indicate future events or trends and which do not relate solely to historical matters. Examples of these forward-looking statements include (but are not limited to) West's statements with respect to planned expansions and job creation. While forward-looking statements reflect West's good faith beliefs, assumptions and expectations, they are not guarantees of future performance. Furthermore, except as required by law, West disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions, new information or other changes. Known material risks, uncertainties and other factors that can affect future results are discussed or incorporated by reference in periodic reports under the Securities Exchange Act of 1934, as amended, filed by West from time to time with the Securities and Exchange Commission.

Media Contact:
Emily Denney
West Global Communications
+1-610-594-3035
[email protected]

Logo - http://photos.prnewswire.com/prnh/20131029/NE05658LOGO

SOURCE West Pharmaceutical Services, Inc.

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.